Occurrence of Carcinoma of the Pancreas Following Nilotinib Therapy for Chronic Myeloid Leukemia: Report of a Case with Review of the Literature.

Abstract

The patient, a 79-year-old Japanese man, was diagnosed with the chronic phase of chronic myeloid leukemia and begun on nilotinib therapy in April 2011. The therapeutic response was major molecular response in August. About 19 months after the start of nilotinib therapy at 400 mg/day (November 2012), an adenocarcinoma (24 x 20 mm) confined to the head of the pancreas developed. In February 2013, a pancreaticoduodenectomy was performed. The therapy regimen was switched to dasatinib at 100 mg/day, beginning in April. The response was still major molecular response with no recurrence of pancreatic carcinoma in July 2013. There have been 29 reported cases of secondary neoplasms associated with nilotinib therapy. These secondary neoplasms were characterized by relatively frequent occurrence of papilloma (6 cases), gastric cancer (3 cases), fibroma (3 cases), and thyroid neoplasms (2 cases). The present case, however, is the first to be reported as carcinoma of the pancreas. This report describes the case.

• Authors: Yasunobu Sekiguchi, Asami Shimada, Moe Matsuzawa, Hidenori Imai, Mutsumi Wakabayashi, Keiji Sugimoto, Noriko Nakamura, Tomohiro Sawada, Junichi Arita, Norio Komatsu, Masaaki Noguchi
• Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology (Turk J Haematol) Vol. 32 Issue 3 Pg. 257-62 (Sep 2015) ISSN: 1308-5263 [Electronic] Turkey
• PMID: 26376592 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Pyrimidines
• nilotinib
• Dasatinib

Topics

• Adenocarcinoma (chemically induced, epidemiology, surgery)
• Aged
• Antineoplastic Agents (adverse effects, pharmacology, therapeutic use)
• Causality
• Clinical Trials as Topic
• Dasatinib (therapeutic use)
• Depression (chemically induced)
• Drug Substitution
• Fibroma (epidemiology)
• Hemangioma
• Humans
• Leukemia, Myeloid, Chronic-Phase (blood, drug therapy)
• Liver Neoplasms
• Male
• Neoplasms, Second Primary (chemically induced, drug therapy, epidemiology, surgery)
• Pancreatic Neoplasms (chemically induced, epidemiology, surgery)
• Pancreaticoduodenectomy
• Pancreatitis (chemically induced)
• Papilloma (epidemiology)
• Pyrimidines (adverse effects, pharmacology, therapeutic use)
• Stomach Neoplasms (epidemiology)
• Thyroid Neoplasms (epidemiology)